Skip to content
thestock.space

On 6 Nov 2026, Sandu Pharmaceuticals was priced at ₹36.72, or 18.7× trailing earnings, against an industry P/E of 28.7×, and the shares are 27% below their 52-week high. Its ROCE of 6.1% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 2.3% and 5.1% a year over 3 years. It has almost no debt, and its dividend yield is 2.7%. It is a small-cap company with a market cap of ₹35 Cr, ranked 137th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 16% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹37.99
Day high
₹37.99
Day low
₹36.00
Prev. close
₹36.99
Volume
3.8K

Health check

2 good · 4 to check
  • ReturnsBehind

    −16.4% over a year, better than 0 of 7 peers.

  • Price tagCheaper

    P/E 18.7 vs industry 28.7.

  • GrowthSlow

    Sales +2.3%, profit +5.1% a year over 3 years.

  • ProfitabilityWeak

    ROCE 6.1% vs peer median 17.9%.

  • Balance sheetSolid

    Practically debt-free, Piotroski 9 of 9.

  • Red flags2 to check

    Return on equity is low at 4.1%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹35 Cr, #137 of 154 in its industry by size.

Defensive

Beta 0.37 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹70 Cr · profit ₹2 Cr
Market cap
₹35 Cr
Small cap
P/E
18.7
Industry 28.7
Price to book
0.91
Peers 4.99
Dividend yield
2.72%
ROE
4.1%
Peers 14.7%
ROCE
6.1%
Peers 17.9%
Debt to equity
0.01
Debt ₹0.42 Cr
EPS (TTM)
₹1.96
OPM (TTM)
4.3%
Net margin 2.5%
Sales growth
−1.9%
Latest quarter vs a year ago
Profit growth
+2.2%
Latest quarter vs a year ago
Price to sales
0.51
EV/EBITDA 5.3

Strengths and risks

Strengths

  • Practically debt-free.
  • Dividend yield of 2.72%.
  • P/E of 18.7 against an industry P/E of 28.7.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 4.1%.
  • Quarterly sales down 1.9% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Sandu Pharmaceuticals

Sandu Pharmaceuticals Limited manufactures and sells ayurvedic medicines under the SANDU brand in India and internationally. It offers immunity monsoon kit, sandu balm, sandu aptilift, sandu mahasudarshan kadha, sandu abhayarishta, sandu pathyadi kadha, sandu makarprash, sandu gulkand pravalyukta, sandu acivin herbal antacid, sandu ashwagandharishta, sandu amritarishta, sandu hemocleen excellent blood purifier, and sandu vanari granules. The company also…

Headquarters
Mumbai
Employees
258
Sector
Healthcare
ISIN
INE751D01014
Website
sandu.in

Price range

52 weeks

₹30.00₹50.00

Today

₹36.00₹37.99
Avg volume (3M)
3K
1-year return
minus 16.4%
From 52-week high
minus 26.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
SANDUPHQSandu Pharmaceuticals36.72minus 0.73%3518.70.916.1%4.1%4.3%2.3%5.1%2.72%minus 16.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
16.717.618.816.916.4
16.216.817.716.315.9
0.50.910.60.5
3.1%4.9%5.5%3.4%3.3%
0000.40
00000
0.20.20.20.20.2
0.30.70.90.70.4
34.1%26.6%−14.0%94.6%36.7%
0.20.5100.2
0.230.541.010.040.37

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+2.3%
Profit CAGR 3Y
+5.1%
EPS CAGR 3Y
+4.1%
ROE
4.1%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
65.367.367.269.9
–+3.0%minus 0.1%+4.1%
62.96564.466.6
2.52.32.83.3
3.8%3.4%4.1%4.7%
0.30.40.20.4
0.10.10.10.1
0.50.60.70.7
–––−0.3
2.22.12.22.7
31.4%29.5%28.2%33.5%
1.51.51.51.8
–minus 3.9%+6.0%+14.0%
1.621.511.601.83

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
9.79.79.79.7
29.630.932.434
–0.10.50.4
14.911.813.211.8
54.252.455.755.9
1717.818.118.1
0.4––0.1
11.612.211.312.3
2.31.22.76.9
22.921.123.718.5
54.252.455.755.9

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
0.20.816.1
0.5−1.3−0.2−0.6
0.6−0.7−0.5−0.9
1.3−1.30.34.6
−1.1−1.4−0.9−0.7
−0.8−0.705.4
−0.7−0.7−0.8−0.8

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you